ArticleFrontiers in aging neuroscience2014
MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging.
Article in Frontiers in aging neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biomarkers for the diagnosis of Alzheimer's disease, dementia Lewy body, frontotemporal dementia and vascular dementia.General psychiatry · 2019Pooled it
- Plasma repressor element 1-silencing transcription factor levels are decreased in patients with Alzheimer's disease.BMC geriatrics · 2022Article
- Easy Identification of Optimal Coronal Slice on Brain Magnetic Resonance Imaging to Measure Hippocampal Area in Alzheimer's Disease Patients.BioMed research international · 2020Article
- A new age-related cutoff of medial temporal atrophy scale on MRI improving the diagnostic accuracy of neurodegeneration due to Alzheimer's disease in a Chinese population.BMC geriatrics · 2019Article
- Inter-method and anatomical correlates of episodic memory tests in the Alzheimer's Disease spectrum.PloS one · 2019Article
- AVRA: Automatic visual ratings of atrophy from MRI images using recurrent convolutional neural networks.NeuroImage. Clinical · 2019Article
- Imaging Biomarkers in Alzheimer's Disease: A Practical Guide for Clinicians.Journal of Alzheimer's disease reports · 2017Review
- Article
- Article
- Biomarkers in neurodegenerative disorders: translating research into clinical practice.Frontiers in aging neuroscience · 2014Article
- Feasibility of the Medial Temporal lobe Atrophy index (MTAi) and derived methods for measuring atrophy of the medial temporal lobe.Frontiers in aging neuroscience · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeDespite a strong correlation to severity of AD pathology, the measurement of medial temporal lobe atrophy (MTA) is not being widely used in daily clinical practice as a criterion in the diagnosis of prodromal and probable AD. This is mainly because the methods available to date are sophisticated and difficult to implement for routine use in most hospitals-volumetric methods-or lack objectivity-visual rating scales. In this pilot study we aim to describe a new, simple and objective method for measuring the rate of MTA in relation to the global atrophy using clinically available neuroimaging and describe the rationale behind this method. DESCRIPTION: This method consists of calculating a ratio with the area of 3 regions traced manually on one single coronal MRI slide at the level of the interpeduncular fossa: (1) the medial temporal lobe (MTL) region (A); (2) the parenchima within the medial temporal region, that includes the hippocampus and the parahippocampal gyrus-the fimbria taenia and plexus choroideus are excluded-(B); and (3) the body of the ipsilateral lateral ventricle (C). Therefrom we can compute the ratio "Medial Temporal Atrophy index" at both sides as follows: MTAi = (A - B)× 10/C.
conclusionsThe MTAi is a simple 2D-method for measuring the relative extent of atrophy in the MTL in relation to the global brain atrophy. This method can be useful for a more accurate diagnosis of AD in routine clinical practice. Further studies are needed to assess the usefulness of MTAi in the diagnosis of early AD, in tracking the progression of AD and in the differential diagnosis of AD with other dementias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.